Walleye Capital
ITCI icon

Walleye Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Walleye Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-383,591
Closed -$32M – 5339
2024
Q4 		$32M Buy
383,591
+134,203
+54% +$11M 0.08% 197
2024
Q3 		$18.2M Buy
249,388
+13,601
+6% +$1.02M 0.04% 373
2024
Q2 		$16.1M Buy
235,787
+80,649
+52% +$5.59M 0.03% 468
2024
Q1 		$10.7M Buy
+155,138
New +$10.7M 0.02% 789
2023
Q4 		– Sell
-134,655
Closed -$7.75M – 5635
2023
Q3 		$7.01M Buy
+134,655
New +$7.84M 0.02% 801
2023
Q2 		– Sell
-226,402
Closed -$14.1M – 4972
2023
Q1 		$12.3M Buy
226,402
+16,690
+8% +$807K 0.18% 110
2022
Q4 		$11.1M Buy
209,712
+4,149
+2% +$208K 0.2% 107
2022
Q3 		$9.56M Buy
205,563
+108,153
+111% +$5.65M 0.18% 119
2022
Q2 		$5.56M Buy
97,410
+27,691
+40% +$1.57M 0.15% 150
2022
Q1 		$4.27M Buy
69,719
+51,841
+290% +$2.69M 0.11% 190
2021
Q4 		$936K Sell
17,878
-86,547
-83% -$3.64M 0.03% 636
2021
Q3 		$3.89M Buy
104,425
+16,772
+19% +$583K 0.11% 123
2021
Q2 		$3.58M Buy
87,653
+23,599
+37% +$872K 0.12% 132
2021
Q1 		$2.17M Sell
64,054
-1,346
-2% -$46.7K 0.13% 131
2020
Q4 		$2.08M Buy
+65,400
New +$1.72M 0.14% 121
2020
Q1 		– Sell
-41,068
Closed -$1.41M – 1805
2019
Q4 		$1.41M Buy
41,068
+22,768
+124% +$273K 0.09% 301
2019
Q3 		$137K Buy
+18,300
New +$175K 0.01% 1336
2019
Q2 		– Sell
-7,605
Closed -$92K – 2133
2019
Q1 		$92K Buy
+7,605
New +$97.2K 0.02% 1062

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HBK Investments
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Walleye Capital's ITCI Position: Q1 2025 in Review

Walleye Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 383,591 shares — an estimated $32M sold.

Walleye Capital first reported a position in ITCI in Q1 2019 and held it in 18 quarters. The position peaked at $32M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Walleye Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 383,591 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $32M.
  • Walleye Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2019 and held it in 18 quarters.
  • Walleye Capital's Intra-Cellular Therapies Inc. position peaked at $32M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.